Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

IMMUPHARMA ATTENDING BIO-EUROPE

27th Oct 2025 07:00

RNS Number : 8330E
Immupharma PLC
27 October 2025
 

RNS REACH : 27 NOVEMBER 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

IMMUPHARMA ATTENDING BIO-EUROPE3-5 November 2025, Vienna

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe Conference in Vienna, from 3-5 November 2025.

BIO-Europe Vienna 2025, is the 31st annual premier biopharma partnering event. It brings together over 5,700 life science professionals from more than 3,000 companies across 60+ countries, facilitating more than 30,000 one-to-one meetings. This event makes it the leading life science partnering forum in Europe, fostering innovation, collaboration and growth in the biotech sector.

For further information please contact:

 

ImmuPharma PLC (www.immupharma.co.uk)

Tim McCarthy, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

 

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 20 3650 3650

+44 (0) 1483 413500

 

 

 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk.

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABRBDGCXDDGUS

Related Shares:

Immupharma
FTSE 100 Latest
Value9,696.74
Change42.92